Literature DB >> 16908675

Transjugular intrahepatic portosystemic shunt patency and clinical outcome in patients with Budd-Chiari syndrome: covered versus uncovered stents.

Roberto Gandini1, Daniel Konda, Giovanni Simonetti.   

Abstract

PURPOSE: To retrospectively compare primary patency and reintervention rates, clinical outcome, and improvement in hepatic dysfunction (Child-Pugh score) in patients with Budd-Chiari syndrome treated with transjugular intrahepatic portosystemic shunt (TIPS) using bare stents or expanded polytetrafluoroethylene (PTFE)-covered stents.
MATERIALS AND METHODS: Approval of study and treatment protocol and waiver of informed consent for the retrospective study were obtained from institutional review board. Informed consent was obtained from each patient before procedure. Four male and nine female consecutive patients (mean age, 35.7 years) with Budd-Chiari syndrome treated with TIPS from January 1994 to November 2003 were included. In six patients, TIPS creation was performed with bare stents (group A). After April 2001, TIPS creation was performed in seven patients with expanded PTFE-covered stent-grafts (group B). Follow-up (group A mean, 22.7 months +/- 10.53 [standard deviation]; group B mean, 23.1 months +/- 7.81) was performed at 7 days, 30 days, and 3 months and subsequently every 3 months. Liver function was evaluated every 3 months. Primary end points were 6- and 12-month TIPS patency rates. Secondary end points were reintervention rate and clinical outcome. Patency rates were estimated (Kaplan-Meier method) and compared (log-rank test). Continuous (Mann-Whitney U test) and categoric (chi(2) test) data were compared. Significant differences before and after treatment were determined (Wilcoxon test).
RESULTS: Mean primary patency duration was 4.46 months +/- 3.40 in group A and 22.29 months +/- 8.15 in group B. In group B, a significant increase in primary patency rate (100% and 85.7% vs 16.7% and 0% at 6 and 12 months; P < .001, log-rank test) and a decrease in reintervention rate (0.29 +/- 0.49 vs 6.17 +/- 1.72, P < .001) were observed. Both groups had a significantly decreased Child-Pugh score; group B had a more persistent and significantly higher reduction.
CONCLUSION: Expanded PTFE-covered stent-grafts significantly increased primary patency rate of TIPS in patients with Budd-Chiari syndrome, with reduced reintervention rate and prolonged clinical improvement. (c) RSNA, 2006.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16908675     DOI: 10.1148/radiol.2411050347

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  16 in total

Review 1.  [Portosystemic shunt surgery between TIPS and liver transplantation].

Authors:  G Puhl; S Gül; P Neuhaus
Journal:  Chirurg       Date:  2011-10       Impact factor: 0.955

2.  Portal hypertension - Role of transjugular liver biopsy and TIPS.

Authors:  Kamal Pathak; Deep Yadav
Journal:  Med J Armed Forces India       Date:  2013-04

Review 3.  Selection of a TIPS stent for management of portal hypertension in liver cirrhosis: an evidence-based review.

Authors:  Xing-Shun Qi; Ming Bai; Zhi-Ping Yang; Dai-Ming Fan
Journal:  World J Gastroenterol       Date:  2014-06-07       Impact factor: 5.742

4.  Emergency Transjugular Intrahepatic Portosystemic Shunt: an Effective and Safe Treatment for Uncontrolled Variceal Bleeding.

Authors:  Yongjun Zhu; Xiaoze Wang; Xiaotan Xi; Xiao Li; Xuefeng Luo; Li Yang
Journal:  J Gastrointest Surg       Date:  2019-02-21       Impact factor: 3.452

5.  Budd-Chiari syndrome: a single-center experience.

Authors:  Tanya M Pavri; Alan Herbst; Rajender Reddy; Kimberly A Forde
Journal:  World J Gastroenterol       Date:  2014-11-21       Impact factor: 5.742

6.  A single-institution review of portosystemic shunts in children: an ongoing discussion.

Authors:  J B Lillegard; A M Hanna; T J McKenzie; C R Moir; M B Ishitani; D M Nagorney
Journal:  HPB Surg       Date:  2010-05-06

7.  Treatment of Budd-Chiari syndrome with transjugular intrahepatic portosystemic shunt (TIPS).

Authors:  R Corso; M Intotero; M Solcia; M C Castoldi; A Rampoldi
Journal:  Radiol Med       Date:  2008-07-09       Impact factor: 3.469

8.  Transjugular intrahepatic portosystemic shunt in the management of complications of portal hypertension.

Authors:  Thomas D Boyer
Journal:  Curr Gastroenterol Rep       Date:  2008-02

9.  Budd-Chiari syndrome: consensus guidance of the Asian Pacific Association for the study of the liver (APASL).

Authors:  Akash Shukla; Ananta Shreshtha; Amar Mukund; Chhagan Bihari; C E Eapen; Guohong Han; Hemant Deshmukh; Ian Homer Y Cua; Cosmas Rinaldi Adithya Lesmana; Mamun Al Meshtab; Masayoshi Kage; Roongruedee Chaiteeraki; Sombat Treeprasertsuk; Suprabhat Giri; Sundeep Punamiya; Valerie Paradis; Xingshun Qi; Yasuhiko Sugawara; Zaigham Abbas; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2021-07-08       Impact factor: 6.047

10.  Construction of Transjugular Intrahepatic Portosystemic Shunt: Bare Metal Stent/Stent-graft Combination versus Single Stent-graft, a Prospective Randomized Controlled Study with Long-term Patency and Clinical Analysis.

Authors:  Chang-Ming Wang; Xuan Li; Jun Fu; Jing-Yuan Luan; Tian-Run Li; Jun Zhao; Guo-Xiang Dong
Journal:  Chin Med J (Engl)       Date:  2016-06-05       Impact factor: 2.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.